According to the Centers for Disease Control and Prevention (CDC), nearly four million babies are born each year in the U.S. Every baby is screened for 33 treatable disorders every year about 13000 babies receive a diagnosis. State and local departments are improving their capacities to handle different types of emergencies calling for new methods and private healthcare players to invest in the newborn screening market.
Congenital diseases can lead to lifelong health challenges in newborns if not treated at an early stage. Advancements in genomic technologies are contributing to new possibilities in newborn screening processes. With a broader range of genetic mutations, diseases can be cured by timely interventions.
The newborn screening market is projected to grow at a lucrative CAGR of 9.4% from 2022 to 2030. Among other factors impacting on need for advanced newborn screening include – rising maternal age, sedentary lifestyles, and climate change imposing threats to health. Healthcare policymakers are realizing the importance of investing in preventive measures and are incorporating new techniques for screening newborns.
The demand for newborn screening varies as per the regulations from region to region. Some countries perform screening for wide-ranging disorders while other countries only target some diseases. Variations in standardized protocols can affect on demand for the newborn screening market.
Author’s Bio:
Amelia Bell:
Senior Market Research expert at The Insight Partners
